Opus Genetics Net Income
| IRD Stock | 3.64 0.00 0.00% |
As of the 16th of February 2026, Opus Genetics holds the Risk Adjusted Performance of 0.1755, coefficient of variation of 483.07, and Semi Deviation of 3.81. Opus Genetics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Opus Genetics information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Opus Genetics is priced some-what accurately, providing market reflects its current price of 3.64 per share. Given that Opus Genetics has jensen alpha of 1.01, we recommend you to check out Opus Genetics's recent market performance to make sure the company can sustain itself at a future point.
Opus Genetics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 15.0986 | Revenue | Earnings Share (1.86) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -51.8 M | -49.2 M | |
| Net Loss | -51.8 M | -49.2 M | |
| Net Loss | (1.94) | (2.04) | |
| Net Income Per E B T | 0.90 | 0.79 |
Opus | Net Income | Build AI portfolio with Opus Stock |
Analyzing Opus Genetics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Opus Genetics's current valuation and future prospects.
Latest Opus Genetics' Net Income Growth Pattern
Below is the plot of the Net Income of Opus Genetics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Opus Genetics financial statement analysis. It represents the amount of money remaining after all of Opus Genetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Opus Genetics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Opus Genetics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (57.53 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Opus Net Income Regression Statistics
| Arithmetic Mean | (17,270,686) | |
| Geometric Mean | 12,194,612 | |
| Coefficient Of Variation | (129.15) | |
| Mean Deviation | 18,054,145 | |
| Median | (6,169,000) | |
| Standard Deviation | 22,305,300 | |
| Sample Variance | 497.5T | |
| Range | 75.4M | |
| R-Value | (0.60) | |
| Mean Square Error | 339.1T | |
| R-Squared | 0.36 | |
| Significance | 0.01 | |
| Slope | (2,654,276) | |
| Total Sum of Squares | 7960.4T |
Opus Net Income History
Other Fundumenentals of Opus Genetics
Opus Genetics Net Income component correlations
Opus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Opus Genetics is extremely important. It helps to project a fair market value of Opus Stock properly, considering its historical fundamentals such as Net Income. Since Opus Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Opus Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Opus Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Opus diversify its offerings? Factors like these will boost the valuation of Opus Genetics. Market participants price Opus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Opus Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Opus Genetics requires distinguishing between market price and book value, where the latter reflects Opus's accounting equity. The concept of intrinsic value - what Opus Genetics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Opus Genetics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Opus Genetics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Opus Genetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Opus Genetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Opus Genetics.
| 11/18/2025 |
| 02/16/2026 |
If you would invest 0.00 in Opus Genetics on November 18, 2025 and sell it all today you would earn a total of 0.00 from holding Opus Genetics or generate 0.0% return on investment in Opus Genetics over 90 days. Opus Genetics is related to or competes with Acumen Pharmaceuticals, Seer, Agenus, Inovio Pharmaceuticals, VistaGen Therapeutics, TuHURA Biosciences, and Alector. Opus Genetics is entity of United States More
Opus Genetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Opus Genetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Opus Genetics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.59 | |||
| Information Ratio | 0.1934 | |||
| Maximum Drawdown | 22.4 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 9.77 |
Opus Genetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Opus Genetics' standard deviation. In reality, there are many statistical measures that can use Opus Genetics historical prices to predict the future Opus Genetics' volatility.| Risk Adjusted Performance | 0.1755 | |||
| Jensen Alpha | 1.01 | |||
| Total Risk Alpha | 0.6704 | |||
| Sortino Ratio | 0.2162 | |||
| Treynor Ratio | 1.57 |
Opus Genetics February 16, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1755 | |||
| Market Risk Adjusted Performance | 1.58 | |||
| Mean Deviation | 3.96 | |||
| Semi Deviation | 3.81 | |||
| Downside Deviation | 4.59 | |||
| Coefficient Of Variation | 483.07 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.28 | |||
| Information Ratio | 0.1934 | |||
| Jensen Alpha | 1.01 | |||
| Total Risk Alpha | 0.6704 | |||
| Sortino Ratio | 0.2162 | |||
| Treynor Ratio | 1.57 | |||
| Maximum Drawdown | 22.4 | |||
| Value At Risk | (7.41) | |||
| Potential Upside | 9.77 | |||
| Downside Variance | 21.02 | |||
| Semi Variance | 14.48 | |||
| Expected Short fall | (4.43) | |||
| Skewness | 0.4503 | |||
| Kurtosis | 0.5686 |
Opus Genetics Backtested Returns
Opus Genetics is unstable given 3 months investment horizon. Opus Genetics maintains Sharpe Ratio (i.e., Efficiency) of 0.24, which implies the firm had a 0.24 % return per unit of risk over the last 3 months. We were able to interpolate data for twenty-seven different technical indicators, which can help you to evaluate if expected returns of 1.19% are justified by taking the suggested risk. Use Opus Genetics Coefficient Of Variation of 483.07, semi deviation of 3.81, and Risk Adjusted Performance of 0.1755 to evaluate company specific risk that cannot be diversified away. Opus Genetics holds a performance score of 18 on a scale of zero to a hundred. The company holds a Beta of 0.67, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Opus Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Opus Genetics is expected to be smaller as well. Use Opus Genetics expected short fall, and the relationship between the value at risk and rate of daily change , to analyze future returns on Opus Genetics.
Auto-correlation | 0.14 |
Insignificant predictability
Opus Genetics has insignificant predictability. Overlapping area represents the amount of predictability between Opus Genetics time series from 18th of November 2025 to 2nd of January 2026 and 2nd of January 2026 to 16th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Opus Genetics price movement. The serial correlation of 0.14 indicates that less than 14.0% of current Opus Genetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.14 | |
| Spearman Rank Test | 0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Opus Operating Income
Operating Income |
|
Based on the recorded statements, Opus Genetics reported net income of (57.53 Million). This is 116.86% lower than that of the Pharmaceuticals sector and 182.13% lower than that of the Health Care industry. The net income for all United States stocks is 110.08% higher than that of the company.
Opus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Opus Genetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Opus Genetics could also be used in its relative valuation, which is a method of valuing Opus Genetics by comparing valuation metrics of similar companies.Opus Genetics is currently under evaluation in net income category among its peers.
Opus Genetics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Opus Genetics from analyzing Opus Genetics' financial statements. These drivers represent accounts that assess Opus Genetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Opus Genetics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 19.2M | 25.7M | 27.9M | 31.8M | 28.6M | 16.0M | |
| Enterprise Value | (4.8M) | (16.9M) | (22.7M) | 1.5M | 1.7M | 1.8M |
Opus Genetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Opus Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Opus Genetics' managers, analysts, and investors.Environmental | Governance | Social |
Opus Fundamentals
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 220.94 M | ||||
| Shares Outstanding | 68.96 M | ||||
| Shares Owned By Insiders | 14.77 % | ||||
| Shares Owned By Institutions | 32.70 % | ||||
| Number Of Shares Shorted | 664.2 K | ||||
| Price To Book | 42.01 X | ||||
| Price To Sales | 17.16 X | ||||
| Revenue | 10.99 M | ||||
| Gross Profit | (12.79 M) | ||||
| EBITDA | (57.52 M) | ||||
| Net Income | (57.53 M) | ||||
| Total Debt | 18.84 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (25.58 M) | ||||
| Short Ratio | 1.01 X | ||||
| Earnings Per Share | (1.86) X | ||||
| Target Price | 7.75 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.59 | ||||
| Market Capitalization | 251.03 M | ||||
| Total Asset | 36.86 M | ||||
| Retained Earnings | (139 M) | ||||
| Working Capital | 25.32 M | ||||
| Net Asset | 36.86 M |
About Opus Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Opus Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Opus Genetics is a strong investment it is important to analyze Opus Genetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Opus Genetics' future performance. For an informed investment choice regarding Opus Stock, refer to the following important reports:Check out For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Pharmaceuticals sector continue expanding? Could Opus diversify its offerings? Factors like these will boost the valuation of Opus Genetics. Market participants price Opus higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Opus Genetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
Understanding Opus Genetics requires distinguishing between market price and book value, where the latter reflects Opus's accounting equity. The concept of intrinsic value - what Opus Genetics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Opus Genetics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Opus Genetics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.